Claims for Patent: 9,415,004

Summary for Patent: 9,415,004

Title:	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
Abstract:	Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
Inventor(s):	Imran; Mir (Los Altos Hills, CA)
Assignee:	Rani Therapeutics, LLC (San Jose, CA)
Application Number:	13/538,912
Patent Claims:	1. A solid tissue penetrating member fabricated from a therapeutic preparation comprising adalimumab, the solid tissue penetrating member shaped and configured to be inserted into the intestinal wall after oral ingestion wherein upon insertion, the preparation releases adalimumab into the blood stream from the intestinal wall to achieve a C.sub.max in a shorter time period than a time period to achieve a C.sub.max for an extravascularly injected dose of adalimumab. 2. The tissue penetrating member of claim 1, wherein a t.sub.max for the adalimumab released from the therapeutic preparation is 80% of a t.sub.max for the extravascularly injected dose of adalimumab. 3. The tissue penetrating member of claim 1, wherein a t.sub.max for the adalimumab released from the therapeutic preparation is 50% of a t.sub.max for the extravascularly injected dose of adalimumab. 4. The tissue penetrating member of claim 1, wherein a t.sub.max for the adalimumab released from the therapeutic preparation is 30% of a t.sub.max for the extravascularly injected dose of adalimumab. 5. The tissue penetrating member of claim 1, wherein a t.sub.max for the adalimumab released from the therapeutic preparation is 10% of a t.sub.max for the extravascularly injected dose of adalimumab. 6. The tissue penetrating member of claim 1, wherein the preparation is adapted for insertion into the wall of the small intestine. 7. The tissue penetrating member of claim 1, wherein the extravascular injection is a subcutaneous injection or an intramuscular injection. 8. The tissue penetrating member of claim 1, wherein the tissue penetrating member is adapted to be orally delivered in a swallowable capsule. 9. The tissue penetrating member of claim 8, wherein the tissue penetrating member is adapted to be operably coupled to delivery means having a first configuration and a second configuration, the tissue penetrating member being contained within the capsule in the first configuration and advanced out of the capsule and into the intestinal wall in the second configuration. 10. The tissue penetrating member of claim 9, wherein the delivery means comprises a least one expandable balloon having an expanded and a non-expanded state and the first configuration is the non-expanded state and the second configuration is the expanded state. 11. The tissue penetrating member of claim 1, wherein the preparation comprises a biodegradable material which degrades within the intestinal wall to release adalimumab into the blood stream. 12. The tissue penetrating member of claim 1, wherein the biodegradable material comprises PGLA, a sugar or maltose. 13. The tissue penetrating member of claim 1, wherein the preparation comprises at least one pharmaceutical excipient. 14. The tissue penetrating member of claim 13, wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant. 15. The tissue penetrating member of claim 14, wherein the binder comprises PEG. 16. The tissue penetrating member of claim 1, wherein the tissue penetrating member comprises a biodegradable material which degrades within the intestinal wall to release adalimumab into the blood stream. 17. The tissue penetrating member of claim 16, wherein the biodegradable material comprises maltose or PGLA. 18. The tissue penetrating member of claim 1, wherein a weight percent of adalimumab in the tissue penetrating member comprises between 8 to 12 percent. 19. The tissue penetrating member of claim 1, wherein the tissue penetrating member includes a retaining feature for retaining the tissue penetrating member within the intestinal wall after insertion. 20. The tissue penetrating member of claim 19, wherein the retaining feature comprises at least one of a barb or an inverse taper shape of the tissue penetrating member. 21. The tissue penetrating member of claim 1, wherein the adalimumab is contained in the tissue penetrating member in a shaped section. 22. The tissue penetrating member of claim 21, wherein the shaped section has a cylinder or pellet shape. 23. The tissue penetrating member of claim 1, wherein the tissue penetrating member has a stiffness to be advanced completely into the intestinal wall by the application of a force to the tissue penetrating member. 24. The tissue penetrating member of claim 1, wherein the C.sub.max achieved by delivering the preparation by insertion into the intestinal wall is up to ten times greater than a C.sub.max achieved when the preparation is delivered orally without insertion into the intestinal wall. 25. The tissue penetrating member of claim 1, wherein the C.sub.max achieved by delivering the preparation by insertion into the intestinal wall is 10 to 100 times greater than the C.sub.max achieved when the preparation is delivered orally without insertion into the intestinal wall. 26. The tissue penetrating member of claim 1, wherein the preparation is configured produce a release of adalimumab to produce a selectable t.sub.1/2 in a range of 6 to 24 hours. 27. The tissue penetrating member of claim 1, wherein the preparation is configured produce a release of adalimumab to produce a t.sub.1/2 of 40 days. 28. The tissue penetrating member of claim 1, wherein a dose of adalimumab in the preparation is in a range from 1 to 5 mg. 29. The tissue penetrating member of claim 28, wherein a dose of adalimumab in the preparation is in a range from 2 to 4 mg. 30. A solid tissue penetrating member fabricated from a therapeutic preparation comprising adalimumab, and configured to penetrate and be inserted into an intestinal wall after oral ingestion, wherein upon insertion, the preparation releases adalimumab into the bloodstream from the intestinal wall to achieve a t.sub.1/2 that is greater than a t.sub.1/2 for orally ingested adalimumab that is not inserted into the intestinal wall. 31. The tissue penetrating member of claim 30, wherein the t.sub.1/2 of the adalimumab inserted into the intestinal wall is 10 to 100 times greater than the t.sub.1/2 for the orally ingested adalimumab that is not inserted into the intestinal wall.

Details for Patent 9,415,004

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2030-12-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2030-12-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2030-12-23